INSM

Prezzo Insmed Incorporated

Closed
INSM
$164,38
-$0,12(-0,07%)

*Data last updated: 2026-04-08 00:43 (UTC+8)

As of 2026-04-08 00:43, Insmed Incorporated (INSM) is priced at $164,38, with a total market cap of $35,14B, a P/E ratio of -29,12, and a dividend yield of 0,00%. Today, the stock price fluctuated between $157,00 and $166,88. The current price is 4,70% above the day's low and 1,49% below the day's high, with a trading volume of 1,34M. Over the past 52 weeks, INSM has traded between $157,00 to $166,88, and the current price is -1,49% away from the 52-week high.

INSM Key Stats

Yesterday's Close$163,81
Market Cap$35,14B
Volume1,34M
P/E Ratio-29,12
Dividend Yield (TTM)0,00%
Diluted EPS (TTM)5,98
Net Income (FY)-$1,27B
Revenue (FY)$606,42M
Earnings Date2026-05-14
EPS Estimate0,96
Revenue Estimate$299,64M
Shares Outstanding214,52M
Beta (1Y)1.101

About INSM

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
SectorHealthcare
IndustryBiotechnology
CEOWilliam H. Lewis
HeadquartersBridgewater,NJ,US
Official Websitehttps://www.insmed.com
Employees (FY)1,66K
Average Revenue (1Y)$364,43K
Net Income per Employee-$767,29K

Insmed Incorporated (INSM) FAQ

What's the stock price of Insmed Incorporated (INSM) today?

x
Insmed Incorporated (INSM) is currently trading at $164,38, with a 24h change of -0,07%. The 52-week trading range is $157,00–$166,88.

What are the 52-week high and low prices for Insmed Incorporated (INSM)?

x

What is the price-to-earnings (P/E) ratio of Insmed Incorporated (INSM)? What does it indicate?

x

What is the market cap of Insmed Incorporated (INSM)?

x

What is the most recent quarterly earnings per share (EPS) for Insmed Incorporated (INSM)?

x

Should you buy or sell Insmed Incorporated (INSM) now?

x

What factors can affect the stock price of Insmed Incorporated (INSM)?

x

How to buy Insmed Incorporated (INSM) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Hot Posts su Insmed Incorporated (INSM)

LootboxPhobia

LootboxPhobia

3 ore fa
Investing.com -- Insmed Incorporated(纳斯达克股票代码:INSM)股价在周二盘后交易中下跌2%,此前该公司宣布在2b期临床试验失败后将终止其化脓性汗腺炎项目。 CEDAR研究评估了brensocatib在中度至重度化脓性汗腺炎成年患者中的疗效,但无论是10毫克还是40毫克治疗组均未达到主要或次要疗效终点。该公司表示将终止brensocatib在化脓性汗腺炎领域的开发。 在第16周时,brensocatib 10毫克和40毫克治疗组的参与者脓肿和炎性结节总数较基线分别减少了45.5%和40.3%,而安慰剂组则减少了57.1%。安慰剂组的改善效果优于两个治疗组。 Brensocatib的耐受性良好,未发现新的安全性信号,包括在40毫克治疗组中,这是Insmed迄今为止研究的最高剂量。在为期16周的安慰剂对照治疗期间,10毫克治疗组中有55.4%的患者出现治疗相关不良事件,40毫克治疗组中有42.9%的患者出现治疗相关不良事件,而安慰剂组为45.7%。 CEDAR研究是一项随机、双盲、安慰剂对照的2b期临床试验,在全球72个研究中心招募了214名患者。参与者被随机分配接受brensocatib 10毫克、brensocatib 40毫克或安慰剂,每日一次,持续16周。 Insmed计划在未来的学术会议上公布这些数据。该公司表示,由于缺乏成熟的动物模型,化脓性汗腺炎的临床开发面临特别大的挑战。 _本文由人工智能协助翻译。更多信息,请参见我们的使用条款。_
2
0
0
0
GateLaunch

GateLaunch

18 ore fa
Gate 上币周报速递:2026年3月30日 - 4月5日 🔹 现货:$EDGEX, #R2, $WL, $MEZO, $UNITAS 🔹 合约:$BASED 🔹 TradFi:$BLSH(Bullish)、$HON(霍尼韦尔)、$SOFI(索菲科技)、$HPE(慧与)、$TGT(塔吉特)、$BE(Bloom能源)、$LRCX(泛林集团)、$CL(高露洁)、$BEN(富兰克林资源)、$ACN(埃森哲)、$OKLO(Oklo)、$STRL(斯特林基础设施)、$WPM(惠顿贵金属)、$CLSK(CleanSpark)、$CIM(奇美拉投资)、$UMC(联华电子)、$TRMB(天宝导航)、$TLN(Talen能源)、$HUT(Hut 8 矿业)、$BITF(Bitfarms)、$PEG(公共服务企业集团)、$ISRG(直觉外科)、$CRCL(Circle 互联网)、$CLS(天弘科技)、$VRT(维谛技术)、$UPS(联合包裹)、$CRDO(Credo科技)、$DLTR(美元树)、$EQR(公平住屋)、$IP(国际纸业)、$BLK(贝莱德)、$MAT(美泰)、$ASML(阿斯麦)、$USB(美国合众银行)、$OKTA(Okta)、$LAC(美洲锂业)、$TQQQ(三倍做多纳斯达克ETF)、$TTWO(Take-Two互动软件)、$AALG(美国航空)、$AMD(超威半导体)、$TRV(旅行者保险)、$BRKB(伯克希尔·哈撒韦)、$TTD(The Trade Desk)、$EXPE(亿客行)、$MFA(MFA金融)、$DELL(戴尔科技)、$CDNS(楷登电子)、$GILD(吉利德科学)、$PM(菲利普莫里斯)、$APP(AppLovin)、$COP(康菲石油)、$WBD(华纳兄弟探索)、$BHP(必和必拓)、$CEG(星座能源)、$VST(Vistra能源)、$FCX(自由港麦克莫兰)、$VRTX(福泰制药、$AMGN(安进)、$JBL(捷普科技)、$STX(希捷科技)、$STZ(星座品牌)、$INSM (Insmed)、$DOCU (DocuSign)、$QQQ(景顺 QQQ 信托系列 1 ETF)、$RF(地区金融)、$MPLX (MPLX LP)、$BUD(百威英博)、$SE(冬海集团)、$IBN(印度工业信贷投资银行)、$PSIX (Power Solutions)、$GRAB(Grab 控股)、$REGN(再生元制药)、$MSTR(微策略)、$GLXY (Galaxy Digital)、$UL(联合利华)、$NOW(现在服务公司)、$VZ(威瑞森电信)、$LLY(礼来)、$WY(惠好)、$MOH(Molina 医疗)、$CMCSA(康卡斯特)、$RACE(法拉利)、$ZIM(以星综合航运)、$PVH(PVH 集团)、$RIVN (Rivian)、$PLAY(戴夫与巴斯特娱乐)、$WDC(西部数据)、$SBET (SharpLink)、$TOYOTA(丰田汽车)、$FTNT(飞塔信息)、$HTHT(华住集团)、$MRVL(迈威尔科技)、$BMNR (BitMine)、$QCOM(高通)、$FDX(联邦快递集团)、$HSBC(汇丰)、$NVS(诺华)、$RBLX (Roblox)、$CAH(嘉德诺)、$FUTU(富途)、$ADBE (Adobe)、$COST(开市客)、$SPGI(标普全球)、$FIG (Figma)、$SNAP (Snap)、$WDAY (Workday)、$DAVE (Dave) 🔹参与 $XAUT #CandyDrop 活动,53 盎司黄金奖励等待瓜分 👉 立即参与:https://www.gate.com/candy-drop/detail/XAUT-305
1
2
0
0
SelfRugger

SelfRugger

04-01 08:04
![](https://img-cdn.gateio.im/social/moments-4835cbc912-d16a958e0b-8b7abd-d8d215) Assessing Insmed (INSM) Valuation After Strong One Year Return And Recent Share Price Pullback ============================================================================================== Simply Wall St Mon, February 16, 2026 at 10:08 AM GMT+9 3 min read In this article: INSM +1.77% Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Insmed at a glance ------------------ Insmed (INSM) has drawn investor attention after a strong 1 year total return of 87.6%, alongside a decline of 24.6% over the past 3 months and a decline of 7.8% over the past month. See our latest analysis for Insmed. Despite a very large 3 year total shareholder return, recent share price returns tell a different story, with the stock giving back some gains over the past quarter as investors reassess growth potential and risk around Insmed’s pipeline and valuation. If Insmed’s recent swings have you thinking about where else growth stories might emerge in healthcare, it could be worth scanning our screener of 25 healthcare AI stocks as a starting point for fresh ideas. With Insmed sharing a strong 1 year total return alongside recent pullbacks, and trading below some intrinsic and analyst estimates, the real question is whether the current price offers upside or whether the market already reflects future growth. Most Popular Narrative: 31% Undervalued --------------------------------------- Insmed’s most followed valuation storyline points to a fair value of $215.10 a share versus the last close at $148.75. This places significant focus on how its respiratory platform and late stage assets develop. > _The analysts have a consensus price target of $97.124 for Insmed based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $110.0, and the most bearish reporting a price target of just $89.0._ > > _Read the complete narrative._ Want to see what sits behind that gap between current price, analyst targets and a higher fair value line? The narrative focuses on rapid revenue expansion, a marked shift in margins and a premium future earnings multiple that many investors usually associate with mature commercial franchises. Curious which assumptions need to align for those numbers to work? The full story connects each of those moving parts in detail. **Result: Fair Value of $215.10 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, there is still clear risk that regulatory delays for brensocatib, or tougher payer access than analysts expect, could quickly challenge this underpriced growth story. Find out about the key risks to this Insmed narrative. Another angle on valuation -------------------------- While the popular storyline points to Insmed trading below fair value, the picture looks different when you look at the P/B ratio. At 33.6x versus 7.8x for peers and 2.6x for the wider US biotech group, the current price leans heavily on future success. That raises the question: how comfortable are you with that premium? Story continues See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:INSM P/B Ratio as at Feb 2026 Build Your Own Insmed Narrative ------------------------------- If you look at the numbers and reach a different conclusion, or simply prefer to build your own view from the ground up, you can easily create a custom Insmed story in just a few minutes. After that, you can stress test it with your own assumptions, Do it your way A great starting point for your Insmed research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? ---------------------------------- If Insmed has sharpened your thinking, do not stop here, you could miss other opportunities that better fit your goals and risk comfort. * Spot potential mispricings fast by running through our list of 53 high quality undervalued stocks built from companies with stronger fundamentals than their share prices suggest. * Strengthen your income core by checking out 12 dividend fortresses that can help you focus on higher-yield names with robust payout profiles. * Sleep a little easier by reviewing 84 resilient stocks with low risk scores that screen for businesses with more resilient risk scores and steadier balance sheets. _ This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ _Companies discussed in this article include INSM._ **Have feedback on this article? Concerned about the content? Get in touch with us directly.**_ Alternatively, email editorial-team@simplywallst.com_ Terms and Privacy Policy Privacy Dashboard More Info
0
0
0
0